- Home
- HYPR vs CGTX Comparison
HYPR vs CGTX Comparison
Compare HYPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | CGTX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYPR | CGTX |
|---|---|---|
| Price | $1.06 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $1.28 | ★ $2.88 |
| AVG Volume (30 Days) | 572.6K | ★ 1.0M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,591,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $35.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.22 |
| 52 Week High | $2.22 | $3.83 |
Technical Indicators
Market Signals| Indicator | HYPR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 53.40 |
| Support Level | $0.85 | $1.58 |
| Resistance Level | $1.18 | $1.81 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 59.93 | 78.33 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.